SMCBF yields 2046.77% · JNJ yields 2.13%● Live data
📍 SMCBF pulled ahead of the other in Year 1
Combined, SMCBF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of SMCBF + JNJ for your $10,000?
The Siam Commercial Bank Public Company Limited provides various financial products and services. The company offers various personal banking products and services, including savings, current, fixed deposit, and long term deposit accounts; payroll solutions; home, car, and personal loans; accident, savings, health expense, and other insurance services; debit, credit, prepaid, and gift cards; mutual funds, bonds, debentures, and other investment products; and payment, digital banking, and other services. It also provides corporate banking products and services comprising credit facilities; financial advisory and merger acquisition services; fixed income instrument and underwriting, structured finance, and project finance services; foreign exchange rate risk management, interest rate risk management, and investment solutions; cash management services; custodian, mutual fund supervisory, registrar, escrow and security agency, debenture's holder representative, and custodian net services; and international trade remittance and digital banking services. In addition, the company engages in the office spaces leasing, hire-purchase, vehicle lending and leasing, and research and development businesses. Further, it provides debt collection services; and food ordering platform and other technological solutions. The company provides its products and services through its head office and branch network in Thailand; and through its branches in Singapore, Hong Kong, Laos, Vietnam, China, and the Cayman Islands. The company is headquartered in Bangkok, Thailand.
Full SMCBF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.